RT Journal Article
SR Electronic
T1 The HLA Ligand Atlas - A resource of natural HLA ligands presented on benign tissues
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 778944
DO 10.1101/778944
A1 Ana Marcu
A1 Leon Bichmann
A1 Leon Kuchenbecker
A1 Daniel Johannes Kowalewski
A1 Lena Katharina Freudenmann
A1 Linus Backert
A1 Lena Mühlenbruch
A1 András Szolek
A1 Maren Lübke
A1 Philipp Wagner
A1 Tobias Engler
A1 Sabine Matovina
A1 Jian Wang
A1 Mathias Hauri-Hohl
A1 Roland Martin
A1 Konstantina Kapolou
A1 Juliane Sarah Walz
A1 Julia Velz
A1 Holger Moch
A1 Luca Regli
A1 Manuela Silginer
A1 Michael Weller
A1 Markus W. Löffler
A1 Florian Erhard
A1 Andreas Schlosser
A1 Oliver Kohlbacher
A1 Stefan Stevanović
A1 Hans-Georg Rammensee
A1 Marian Christoph Neidert
YR 2020
UL http://biorxiv.org/content/early/2020/07/09/778944.abstract
AB The human leukocyte antigen (HLA) complex controls adaptive immunity by presenting defined fractions of the intracellular and extracellular protein content to immune cells. Here, we describe the HLA Ligand Atlas, an extensive collection of mostly matched HLA-I and -II ligandomes from 225 benign samples (29 tissues, 21 subjects). The initial release covers 51 HLA-I and 86 HLA-II allotypes presenting 89,853 HLA-I- and 140,861 HLA-II ligands. We observe that the immunopeptidomes differ considerably between tissues and individuals on both source protein and HLA-ligand level. 1,407 HLA-I ligands stem from non-canonical genomic regions. We highlight the importance of comparatively analyzing both benign and malignant tissues to inform tumor association, based on a case study in three glioblastoma patients. The resource provides insights into applied and basic immune-associated questions in the context of cancer immunotherapy, infection, transplantation, allergy, and autoimmunity. It is publicly available at www.hla-ligand-atlas.org.Competing Interest StatementLinus Backert, Daniel Johannes Kowalewski, Maren Lübke are employees of Immatics Biotechnologies GmbH. Linus Backert, Daniel J. Kowalewski, Markus W. Löffler, and Stefan Stevanović are inventors of patents owned by Immatics Biotechnologies GmbH. Markus W. Löffler has acted as a paid consultant in cancer immunology for Boehringer Ingehlheim Pharma GmbH & Co. KG. Hans-Georg Rammensee is shareholder of Immatics Biotechnologies GmbH and Curevac AG.